干细胞治疗缺血性心肌病的临床研究进展

Advances in research of stem cell therapy for ischemic myocardial disease

缺血性心肌病是影响人类健康的主要疾病之一,采用干细胞移植治疗缺血性心肌病已经成为近年来的研究热点。移植干细胞能够促进新生血管形成和心肌组织再生,减少瘢痕面积,改善心肌收缩能力。目前应用干细胞治疗缺血性心肌病的临床试验所得到的治疗结果不尽相同,不同类型的干细胞来源、注射方法及剂量、随访观察时间均可影响临床治疗效果;干细胞移植所涉及的免疫排斥、促肿瘤形成以及其他潜在的安全性问题仍是医学界重点关注的领域。本文就干细胞移植治疗缺血性心肌病临床研究相关的影响因素及其安全问题进行相关阐述。

Ischemic myocardial disease is one of the major diseases affecting human health. Stem cell transplantation for treatment of ischemic myocardial diseases has become a hot research topic in recent years.Transplantation of stem cells can promote angiogenesis and heart tissue regeneration,reduce scarred area,and improve heart systolic function.However,results from clinical studies on stem cell therapy for ischemic myocardial disease are inconsistent,which could result from the source of stem cells,infusion ways,injection dosage,and follow-up time.Additionally,stem cell transplantation is associated with immune rejection,tumor formation,and other potential safety issues.The main objective of this review is to discuss the influencing factors and safety problems in stem cell therapy for ischemic myocardial disease.